Addex Therapeutics Ltd is a Swiss-based biopharmaceutical company focused on the discovery, advancement, and commercialization of small-molecule drug candidates for disorders impacting the central nervous system (CNS). The firm's core scientific endeavor is the development of oral, small-molecule allosteric modulators that interact with G-protein coupled receptors. Its leading therapeutic programs include Dipraglurant, which is being investigated for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, targeting epilepsy and other undisclosed CNS indications; and a GABAB PAM compound for addiction.